Effects of hGRF treatment of a patient with hGRF deficiency.
A 12-year old girl was admitted to our hospital for evaluation of her short stature. Her height was below -3.5 SD of the mean height for her age. She was diagnosed as having craniopharyngioma and treated surgically. Thereafter she was treated with thyroxine and hydrocortisone. One and a half years later, she revisited our hospital for treatment of short stature. Her plasma GH did not respond to insulin-induced hypoglycemia but increased after hGRF-44 administration, indicating hGRF deficiency. hGRF was therefore administered at a dosage of 100 micrograms twice a day subcutaneously for three months. Her height increased 1.6 cm during treatment, which corresponded to a height increase of 6.4 cm/year. These findings indicate that hGRF treatment stimulates height increase in patients with GRF deficiency. For complete evaluation of hGRF therapy, further studies will be required.
D002648:Child; D003397:Craniopharyngioma / Q000601:surgery; D004393:Dwarfism, Pituitary / Q000188:drug therapy*; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007334:Insulin-Like Growth Factor I / Q000097:blood; D010446:Peptide Fragments / Q000627:therapeutic use*; D013974:Thyroxine / Q000008:administration & dosage
D010446:Peptide Fragments; D007334:Insulin-Like Growth Factor I; D013007:Growth Hormone-Releasing Hormone; D013974:Thyroxine; D006854:Hydrocortisone